<DOC>
	<DOC>NCT01609036</DOC>
	<brief_summary>This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) in previously untreated patients with follicular lymphoma. Data will be collected for 3 years</brief_summary>
	<brief_title>An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patients, &gt;/=18 years Patients with previously untreated follicular lymphoma (stage IIIIV) according to the approved summary of product characteristics (SPC) Contraindications to MabThera/Rituxan therapy according to the approved SPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>